At a glance
- Originator Novartis
- Class Antibacterials; Peptide antibiotics; Peptides
- Mechanism of Action Peptide elongation factor Tu inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 28 Aug 2019 Discontinued - Phase-II for Clostridium difficile infections in Canada, USA (PO)
- 02 Sep 2015 Phase-II development is ongoing in USA and Canada
- 20 Sep 2011 Preclinical antimicrobial and pharmacodynamics data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011) ,,